Change in Cardiorespiratory Fitness Linked to Prostate Cancer Incidence
31 Jan 2024
Clinical Result
WEDNESDAY, Jan. 31, 2024 -- Change in cardiorespiratory fitness (CRF) is inversely associated with the risk for prostate cancer incidence, but not mortality, according to a study published online Jan. 30 in the British Journal of Sports Medicine.
Kate A. Bolam, Ph.D., from the Swedish School of Sport and Health Sciences GIH in Stockholm, and colleagues conducted a prospective study to examine the associations between changes in CRF in adulthood and prostate cancer incidence and mortality. The study included men who completed an occupational health profile assessment, including at least two valid submaximal CRF tests.
The researchers found that 592 of the 57,652 men (1 percent) were diagnosed with prostate cancer during a mean follow-up of 6.7 years, and 0.08 percent died with prostate cancer as the primary cause of death. In the fully adjusted model, there was an association seen for an increase in absolute CRF with a reduced risk for prostate cancer incidence (hazard ratio, 0.98), but not mortality. In the fully adjusted model, when participants were categorized as having increased, stable, or decreased CRF (+3, ±3, and −3 percent, respectively), the risk for prostate cancer was reduced for those with increased versus decreased fitness (hazard ratio, 0.65).
"The findings of this study provide further clarity on the associations between CRF and cancer incidence in an area of research with conflicting results," the authors write. "The results of this study highlight the important role of supporting the general public to increase their CRF or aim to reach moderate fitness levels."
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.